Lili Cheng

Title: Lili Cheng: A Trailblazer in NP-1 Antagonist Inventions

Introduction

Lili Cheng is a prominent inventor based in London, GB, recognized for her innovative work in the field of pharmaceutical sciences. With a total of two patents to her name, her contributions to NP-1 antagonistic compounds have made significant strides in medical research and therapeutic applications.

Latest Patents

Lili Cheng's latest patents include groundbreaking inventions relating to arginine derivatives with NP-1 antagonistic activity. The first patent presents a compound defined by formula (I) or formula (II) that demonstrates efficacy as an NP-1 antagonist. Similarly, her second patent also involves compounds of formula (I) or formula (II) suitable for NP-1 antagonists, showcasing her consistent focus on this vital area of research.

Career Highlights

Throughout her career, Lili Cheng has made substantial contributions while working at notable companies such as Ark Therapeutics Limited and Ark Therapeutics Group, Plc. Her role in these organizations has enabled her to push the boundaries of innovation in drug discovery and development.

Collaborations

Lili has collaborated with talented individuals such as Haiyan Jia and Ian Zachary, who have contributed to her research endeavors. These partnerships have enhanced her work on NP-1 antagonists and supported her vision of advancing therapeutic solutions.

Conclusion

In conclusion, Lili Cheng stands out as a key inventor in the pharmaceutical industry, with her patents paving the way for future innovations in NP-1 antagonism. Her dedicated work and collaboration demonstrate her commitment to improving medical therapies and advancing the frontiers of science. Her impact in the field continues to inspire new generations of inventors and researchers.